June 2023
Volume 64, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2023
Characterisation of induced pluripotent stem cell derived retinal organoid models of RDH12-retinopathies
Author Affiliations & Notes
  • Cécile Méjécase
    Institute of Ophthalmology, University College London, London, London, United Kingdom
  • Nicholas Owen
    Institute of Ophthalmology, University College London, London, London, United Kingdom
  • Hajrah Sarkar
    Institute of Ophthalmology, University College London, London, London, United Kingdom
  • Lyes Toualbi
    Institute of Ophthalmology, University College London, London, London, United Kingdom
  • Mariya Moosajee
    Institute of Ophthalmology, University College London, London, London, United Kingdom
    Moorfields Eye Hospital NHS Foundation Trust, London, London, United Kingdom
  • Footnotes
    Commercial Relationships   Cécile Méjécase None; Nicholas Owen None; Hajrah Sarkar None; Lyes Toualbi None; Mariya Moosajee None
  • Footnotes
    Support  Retina UK GR594, Moorfield Eye Charity 569249.S-ACA.183882
Investigative Ophthalmology & Visual Science June 2023, Vol.64, 3194. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Cécile Méjécase, Nicholas Owen, Hajrah Sarkar, Lyes Toualbi, Mariya Moosajee; Characterisation of induced pluripotent stem cell derived retinal organoid models of RDH12-retinopathies. Invest. Ophthalmol. Vis. Sci. 2023;64(8):3194.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Retinal dehydrogenase 12 (RDH12) is a photoreceptor NADPH-dependent retinal reductase enzyme, which converts all-trans-retinal to all-trans-retinol. Mutations in RDH12 are primarily associated with severe early onset autosomal recessive (AR) Leber congenital amaurosis and in rare cases mild late onset autosomal dominant (AD) retinitis pigmentosa. While RDH12 mouse and zebrafish models do not recapitulate the early-onset human phenotype, we developed retinal organoid models derived from human induced pluripotent stem cells (hiPSC), obtained from skin biopsies of one RDH12 AR, one RDH12 AD patients and one unrelated unaffected individual (WT).

Methods : Wild-type, RDH12 AR and RDH12 AD hiPSC were differentiated into retinal organoids and characterised at different stages of differentiation by immunostaining (n=3 per line) with retinal- and photoreceptor-specific markers (CRX, OTX2, RECOVERIN, RHO, LM-opsin), autophagy (LC3), oxidative (8-OHdG, Acrolein) and ER stress (CHOP/DDIT3, BiP/HSPA5) markers and TUNEL assay for cell death. Mature RDH12 mutant retinal organoids were stressed with 100 µM all-trans-retinal for 24 hours and assessed for cell death, autophagy, oxidative and ER stress (n=3 per condition).

Results : Immunofluorescence studies revealed 9-week-old RDH12 mutant retinal organoids produced less CRX, RECOVERIN and OTX2 than wild-type organoids. Both wild-type and RDH12 retinal organoids were grown to week 44, they all developed rod and cone photoreceptors but there was no significant difference in cell death, autophagy, oxidative and ER stress. Moreover, RDH12 mutant organoids were resistant to all-trans-retinal induced stress.

Conclusions : Our study is the first to characterise human RDH12 retinal organoid models but there were few differences between WT and mutants at later stages of photoreceptor differentiation. Further work is required to study the ultrastructure and transcriptomic signature for any intracellular and molecular pathophysiology associated with RDH12-related retinopathies.

This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×